Novo Nordisk Feed

2025-11-08 09:19:11 Novo Nordisk will not increase its proposal to acquire Metsera, Inc.

2025-11-06 19:01:11 Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost 291,20 DKK | -5,13% | 3 169 MDKK

2025-11-05 22:30:00 Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications 306,95 DKK | +1,96% | 2 455 MDKK

2025-11-05 07:30:45 Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues 301,05 DKK | -4,49% | 4 712 MDKK

2025-11-04 15:31:50 Novo Nordisk submits updated proposal to acquire Metsera, Inc. 315,20 DKK | -0,03% | 2 704 MDKK

2025-10-30 10:49:37 Novo Nordisk submits proposal to acquire Metsera, Inc. 322,70 DKK | -3,63% | 2 968 MDKK

2025-10-21 14:02:25 Notice convening an Extraordinary General Meeting of Novo Nordisk A/S 354,95 DKK | -1,35% | 1 426 MDKK

2025-10-21 13:56:30 Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors 354,95 DKK | -1,35% | 1 426 MDKK

2025-10-15 14:30:41 Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906) 363,90 DKK | +0,90% | 1 606 MDKK

2025-10-09 12:00:42 Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio 379,60 DKK | -1,25% | 1 811 MDKK

2025-09-18 10:45:49 Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study 392,50 DKK | +6,22% | 3 725 MDKK

2025-09-17 23:05:17 Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study 392,50 DKK | +6,22% | 3 725 MDKK

2025-09-16 12:00:47 Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme 359,10 DKK | +1,13% | 1 920 MDKK

2025-09-16 00:03:35 People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being 355,10 DKK | +1,95% | 1 937 MDKK

2025-09-15 14:00:52 EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke 355,10 DKK | +1,95% | 1 937 MDKK

2025-09-10 07:00:45 Novo Nordisk to streamline operations and reinvest for growth 351,15 DKK | +3,68% | 2 871 MDKK

2025-09-05 08:01:42 Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress 350,00 DKK | -2,91% | 1 925 MDKK

2025-08-31 09:09:33 Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas

2025-08-20 15:31:00 Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025 345,60 DKK | -0,70% | 1 792 MDKK

2025-08-19 13:37:18 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 348,05 DKK | +0,16% | 2 661 MDKK

2025-08-15 23:23:39 Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

2025-08-12 14:26:06 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 320,50 DKK | -0,65% | 1 894 MDKK

2025-08-08 15:16:00 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 323,05 DKK | +4,60% | 3 700 MDKK

2025-08-07 17:31:05 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 323,05 DKK | +4,60% | 3 700 MDKK

2025-08-06 07:30:41 Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025 289,50 DKK | -5,36% | 6 378 MDKK

2025-07-29 13:36:01 Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk 346,90 DKK | -23,11% | 14 664 MDKK

2025-07-29 13:02:01 Novo Nordisk lowers sales and operating profit outlook for 2025 346,90 DKK | -23,11% | 14 664 MDKK

2025-07-25 12:47:17 European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors 452,10 DKK | +1,13% | 1 784 MDKK

2025-06-23 20:36:26 Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities 453,05 DKK | +0,53% | 1 585 MDKK

2025-06-22 21:35:40 Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress 450,65 DKK | -5,29% | 2 743 MDKK

2025-06-22 15:00:45 Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

2025-06-21 01:38:25 Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA 475,80 DKK | -2,58% | 3 170 MDKK

2025-06-21 01:34:54 Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025 475,80 DKK | -2,58% | 3 170 MDKK

2025-06-12 19:06:19 Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development 516,20 DKK | -0,58% | 2 418 MDKK

2025-06-10 14:00:43 ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care 519,80 DKK | +6,01% | 4 041 MDKK

2025-05-16 13:19:48 Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk 426,55 DKK | -1,81% | 4 455 MDKK

2025-05-16 13:02:00 Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk 426,55 DKK | -1,81% | 4 455 MDKK

2025-05-14 12:59:39 Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases 432,85 DKK | -1,31% | 1 816 MDKK

2025-05-12 08:01:36 Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE 441,40 DKK | -0,65% | 4 430 MDKK

2025-05-09 13:22:54 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 444,30 DKK | +3,59% | 2 125 MDKK

2025-05-07 07:30:45 Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025 446,80 DKK | +1,30% | 3 883 MDKK

2025-05-06 14:00:11 Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases 441,05 DKK | -3,93% | 1 764 MDKK

2025-04-03 08:00:46 Novo Nordisk announces changes in Executive Management 456,85 DKK | -2,09% | 2 257 MDKK

2025-03-29 19:33:37 Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

2025-03-29 15:33:58 Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

2025-03-27 16:17:09 Resolutions from the Annual General Meeting of Novo Nordisk A/S 480,60 DKK | -3,84% | 3 256 MDKK

2025-03-24 11:02:10 The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist 521,70 DKK | -1,34% | 1 826 MDKK

2025-03-10 11:24:12 Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial 549,40 DKK | -8,07% | 5 406 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Novo Nordisk

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden